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Introduction
Breast cancer (BC) in women is the most common 
reason for cancer mortality around the world. The rate of 
this malignancy is varying worldwide, but it is increasing in 
areas that until recently had a low prevalence of the disease 
(Key et al., 2001). Many etiologic factors, including 
nutritional, lifestyle, environmental carcinogenicity, as 
well as oxidative stress have been considered to increase 
the risk of breast cancer (Calaf et al., 2018; Wu et al., 
2018). The role of paraoxonase 1 (PON1) in detoxification 
of cancer-causing oxidative stress encourages scientists to 
evaluate PON1 gene variations in susceptibility to breast 
cancer (Pan et al., 2019). PON1 binds to HDL and helps to 
detoxify organophosphorus compounds such as paraoxon 
and lipid peroxidation-soluble radicals (Shih et al., 1998).
Humans PON1 gene is located on the long arm of 
chromosome 7 (7q21.3) which is contained 9 exons and 
encodes a protein with 355 residues (Deakin et al., 2002). 
Although several pharmaceutical, dietary, and life-style 
modulators of PON1 are identified, by far the main 
influence on the activity of PON1, which could differ by 
above 40 times between persons, is through PON1 genetic 
variations (Costa et al., 2005; Mackness and Mackness, 
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2015). There are several main polymorphisms in PON1 
gene that could affect the gene function. The PON1-Q192R 
(rs662) missense single nucleotide polymorphism (SNP) 
regulates a substrate-dependent influence on activity. 
The 192R isoform could hydrolyze some substrates 
such as paraoxon 192Q isoform could hydrolyze some 
other substrates such as lipid-peroxides and diazoxon 
(Mackness et al., 1998). Both the missense L55M 
(rs854560) and the upstream T-108C (rs705379) SNPs 
are correlated with various activities and serum levels of 
PON1. The PON1-55M isoform leads to a lower level of 
mRNA and then its activity compared to 55L isoform. 
Besides, the -108C genotype of rs705379 variation could 
result in higher promoter activity compared to the -108T 
genotype (Costa et al., 2005; Schrader et al., 2012). 
There are several studies investigating the role of three 
mentioned SNPs with various common malignancies e.g. 
breast cancer. Regarding to the rs854560 polymorphism, 
there are some reports. For example, Stevens et al., (2006) 
reported that this polymorphism might be correlated with 
elevated susceptibility of breast cancer in USA. Naidu et 
al., (2010) suggested that the L55M SNP may be a genetic 
biomarker for breast cancer in Malaysian population. 
However, there is no identified study investigating the 
Editorial Process: Submission:11/14/2019   Acceptance:01/12/2020
Amir Farmohammadi et al
Asian Pacific Journal of Cancer Prevention, Vol 21256
association of this polymorphism with breast cancer in 
Iranian population. This study aimed to investigate the 
association of PON1-L55M genetic polymorphism with 
breast cancer susceptibility in a case-control trial.
Materials and Methods
Subjects
In a hospital-based case-control study, 300 participants 
including 150 subjects with breast cancer and 150 
age-matched healthy controls were enrolled from Pasteur 
pathobiology and genetics laboratory and also Rohani 
hospital (Babol, Iran). The breast cancer diagnosis was 
approved histologically for all breast cancer subjects. 
Healthy controls individuals without oncological history 
were referring to the same hospital for routine tests, and 
after completing the questionnaire and oral interview, it 
became clear that they did not display positive outcomes. 
Lastly, 2 mL peripheral blood was obtained from all 
participants. Besides, the current study was performed 
according to the criteria outlined in the Helsinki 
Declaration. 
SNP genotyping
After, blood sample collection, genomic DNA 
was extracted from whole blood by a commercial Kit 
(Bioneer, Korea) and the PON1-L55M SNP genotyping 
was performed by polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP) method 
according to the previous study (Kocakap et al., 
2016). In brief, PCR was done in a 20 µL overall 
volume. About 50 ng of genomic DNA, 10 µL of 2X 
premix, and 0.1 nmoL of the primers (forward primer: 
5’-GAAGAGTGATGTATAGCCCCAG-3’ and reverse 
primer: 5’-TTTAATCCAGAGCTAATGAAAGCC-3’) 
were used to PCR. After initial denaturation at 95°C for 
5 min, the PCR mixture was subjected to 30 repeatitive 
cycles of denaturation (at 94°C for 1 min), annealing (at 
61°C 45 sec), and extension (at 72°C for 1 min). The 
PCR products with length of 171-bp was treated with the 
NlaIII restriction endonuclease (Fermentas, Germany) 
at 37°C for 16 hours, and the digested mixtures were 
electrophoresed on 2% agarose gel. The T (L) allele had 
no restriction site for NlaIII enzyme, while the A (M) allele 
was digested to 127 and 44-bp fragments.
Statistical analysis
Hardy-Weinberg equilibrium (HWE) was computed in 
both case and control groups by the Chi-Square test. The 
differences of allele and genotype frequencies between 
case and control groups were calculated by Chi-Square 
test. The strength of association between rs854560 
polymorphism and risk of breast cancer was evaluated 
by odds ratios (ORs) and 95% confidence intervals (CIs) 
which were estimated by logistic regression. A p-value 
of less than 0.05 was considered statistically significant. 
These statistical analyses were performed by SPSS 
Statistical software version 19 (SPSS Inc., Chicago, IL, 
USA).
Results
Some demographic and demographic features of 
included patients in our study are presented in table 1. The 
average of age and body mass index (BMI) were estimated 
45.50±7.26 years and 25.10±4.15 kg/m2, respectively. 
Additionally, 41.33% of patients were postmenopausal. 
The highest percentage of histologic grade was related to 
grade I (52.00%). The tumor type for 67.33% of patients 
was detected as invasive ductal carcinoma (IDC) and 
32.00% was detected as invasive lobular carcinoma (ILC). 
While one of the patients was considered with a mixed 
tumor (IDC+ILC). Tumor size in 65.33% of patients was 
less than 2 cm while 34.67% of patients have a tumor with 
size ≥2 cm. Finally, lymph node metastasis was observed 
in 52.00% of patients (Table 1).
Genotype frequencies of PON1-rs854560 variation 
were computed and data examination showed that 
genotypes distribution met the HWE criteria in patient 
(χ2= 2.54; p= 0.111) and control (χ2= 3.37; p= 0.067) 
groups. Table 2 displays frequencies of allele and 
genotype for the rs854560 SNP in our case-control study. 
Frequencies of genotypes LL, LM, and MM were 44.00%, 
39.33%, and 16.67%, respectively for the healthy control 
group and 31.33%, 43.33%, and 25.34% respectively 
for the breast cancer group. Alleles L and M rates were 
63.67% and 36.33% respectively for the control group 
and 53.00% and 47.00% respectively in the breast cancer 
group. As detailed in Table 2, we observed a significant 
association between genotype MM and breast cancer risk 
(OR= 2.13, 95%CI= 1.14-4.00, p= 0.018). In addition, 
Variables Description
Age (years) mean±SD 45.50±7.26
BMI (kg/m2) mean±SD 25.10±4.15
Menopause status
     Yes 62 (41.33%)
     No 88 (58.67%)
Histological grade 
     I 78 (52.00%)
     II 29 (19.33%)
     III 13 (08.67%)
     Not identified 30 (20.00%)
Tumor type
     IDC 101 (67.33%)
     ILC 48 (32.00%)
     IDC+ILC 1 (0.67%)
Tumor size
     <2 cm 98 (65.33%)
     ≥2 cm 52 (34.67%)
Lymph node metastasis
     No 72 (48.00%)
     Yes 78 (52.00%)
BMI, body mass index; SD, standard deviation; IDC, invasive ductal 
carcinoma; ILC, invasive lobular carcinoma
Table 1. Demographic and Pathologic Information of 
Patients 
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the polymorphisms of these genes are key determinants 
of cancer susceptibility to toxic or environmental toxic 
chemicals (Shih et al., 1998; de Jong et al., 2002). Single 
nucleotide polymorphisms based on their gene locations 
could affect the function of the gene (Salimi et al., 2017; 
Nejati et al., 2018). For example, genetic variations in 
promoter regions could affect gene expression level and 
non-coding variation could alter gene expression via 
interfering with splicing procedure (Mobasseri et al., 2019; 
Zamani-Badi et al., 2019). But, the genetic variations 
in coding sequences (exon variations) could affect the 
protein structure and function (Noureddini et al., 2018; 
Bafrani et al., 2019). So based on what was mentioned, 
the L55M polymorphism as an exon variation, could affect 
the protein PON1 structure and/or function. Investigation 
of molecular effects of genetic variation through in vitro 
and in vivo is too cost- and time-consuming. However, the 
computational analysis could be useful to evaluate these 
effects and other molecular evaluations (Tameh et al., 
2018; Zamani-Badi et al., 2018). Therefore, assessment 
of L55M polymorphism on the PON1 protein function by 
using bioinformatics tools could be a helpful approach. 
Our findings suggest that the PON1-L55M 
polymorphism is a genetic risk factor for breast cancer 
risk and it could be considered as a possible molecular 
biomarker for screening of susceptible women. However, 
there are some limitations in case-control study which 
should be mentioned. For example, we did not evaluate 
the gene-gene and gene-environmental factors and also our 
sample size was somewhat small. Besides, combination 
effects of PON1-L55M gene polymorphism and some 
oxidative stress markers such as total antioxidant capacity, 
malondialdehyde with breast cancer could be useful.
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carriers of allele M were at a high risk for breast cancer 
(OR= 1.72, 95%CI= 1.07-2.76, p= 0.024). Besides, allele 
analysis revealed that there is a significant association 
between allele M and breast cancer risk (OR= 1.55, 
95%CI= 1.12-2.15, p= 0.008).
Discussion
Breast cancer is the most common cancer in 
women that the etiology of this malignancy is not fully 
understood. It seems that oxidative stress and free radicals 
play an important role in the pathogenesis and progression 
of breast cancer (Valko et al., 2006; Hecht et al., 2016). In 
this study, we investigated the association of the common 
polymorphism L55M in the PON1 antioxidant gene in a 
case-control study. The data from our experimental study 
revealed that there is a significant association between 
MM, LM+MM, M genotypes and allele and breast cancer 
risk in our studied population. This shows the main role 
of this gene in the development of breast cancer. In a 
meta-analysis published in 2019, it was reported that 
there are significant associations between PON1-L55M 
genetic variation and other cancers such as hematologic 
cancer and prostate cancer (Pan et al., 2019). However, 
there is another key polymorphism in the PON1 gene 
which should be noted. It is Q192R missense variation 
which is associated with decreased risk of breast cancer 
(Pan et al., 2019). 
Oxidative stress could result in impaired in biological 
membranes, intracellular organelles, and macromolecules 
such as proteins and DNA (Essick and Sam, 2010). One 
of the main damage is the oxidation of lipids by free 
radicals resulting from these stresses, which results in 
the production of active compounds such as aldehydes, 
ketones and hydroxyl acids (Valko et al., 2006). These 
radicals may have an external source or may be due 
to oxidation-reduction reactions in the body. The 
imbalance in the formation and removal of these free 
radicals, including reactive oxygen species (ROS), has 
been shown to cause genetic dysfunction, interference 
with cellular signaling, metastasis, neurodegenerative 
diseases, and aging (Allen, 1998). The human body has 
many enzymatic systems for the protection of genotoxic 
damage that activate, indirectly, through the reduction of 
substrates having the potential to produce free radicals, 
such as cytochrome P450c17a or directly via or indirectly, 
through free radical scavenging, such as PON1 (Yu, 
1994; Salama et al., 2008). Therefore, it is accepted that 
Genotype/ Allele No. and  Percentage Chi-square OR (95% CI) p-value
Control (n= 150) Case (n= 150)
LL 66 (44.00%) 47 (31.33%) - - -
LM 59 (39.33%) 65 (43.33%) 2.78 1.55 (0.93-2.59) 0.096
MM 25 (16.67%) 38 (25.34%) 5.68 2.13 (1.14-4.00) 0.018
LM+MM 84 (56.00%) 103 (68.67%) 5.13 1.72 (1.07-2.76) 0.024
L 191 (63.67%) 159 (53.00%) - - -
M 109 (36.33%) 141 (47.00%) 7.02 1.55 (1.12-2.15) 0.008
Table 2. Genotype and Allele Frequensies of rs854560
OR, odds ratio; CI, confidence interval; Significant differences between the case and control groups are bolded.
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